Meeting Highlights from ENDO Online 2020: The Endocrine Society's Virtual Meeting

June 8-22, 2020

Originally, the ENDO-2020 conference was scheduled for March 28-31, in San Franscico, CA, but rescheduled virtually due to COVID. Within weeks, the society transformed the conference to an online format, providing on-demand and live content and renamed it, ENDO Online 2020. The online conference ran from June 8-22 and had more than 17,000 registrants, a number exceeding any live conference previously held.

Despite the drastic change in venue, the Endocrine Society ended up having one of, if not the most, successful ENDO conference yet, thanks to the flexibility of all who participated and the willingness to provide unconventional presentations. Sessions from previous ENDO conferences are available here, with many available free of charge. ENDO 2021 is currently planned for March 20-23, 2021 at the San Diego Convention Center.

While access to the sessions via the ENDO Online 2020 site ended on July 6, society members can watch the sessions through the Endocrine Society Center for Learning.

For non-members, there are five free ancillary ENDO Online 2020 events. These sessions were developed through the Endocrine Society’s Special Programs Committee (SPC) and were supported by independent medical education grants. CME credits are available for these sessions through July 13, 2021.

  • Improving Outcomes in Acromegaly: Let Your Patients Be Your Guide (supported by Chiasma, Inc. and Vindico Medical Education)

Acromegaly is a disorder resulting from excess growth hormone, most often as a result of a pituitary tumor. The session contained three presentations discussing the unique presentation and symptoms associated with acromegaly, surgical and medical treatment options based on patient uniqueness, and lastly the presented clinical cases and outcomes.  The presenters were:

Shlomo Melmed, MD (Cedars Sinai Medical Center, Los Angeles, CA)

Lisa Nachtigall, MD (Neuroendocrine and Pituitary Clinic, Massachusetts General Hospital, Boston, MA)

Adriana Ioachimescu, MD, PhD (Emory Pituitary Center, Emory University School of Medicine, Atlanta, GA)

  • Breaking Bad: Reducing Glucose Variability and Increasing Time in Range in Patients with Diabetes (supported by Novo Nordisk Inc., Abbott Diabetes Care, and Medtronic)

Increasing Time in Range (TIR) to 70% can reduce the physical and mental consequences of extreme hyper- and dangerous hypo-glycemia in diabetic patients. This session discussed the research behind TIR and ways of encouraging patients to care about their TIR, followed by clinical cases. The presenters were:

Steven Edelman, MD (University of California San Diego)

Rayhan A. Lai, MD (Stanford University, CA)

Jeremy H. Pettus, MD. (University of California San Diego)

It is easier to lose weight than it is to sustain long-term weight loss- this phrase flavored the session on weight loss and obesity. Presenters approach obesity as a life-long disease requiring ongoing modification across the patient’s lifespan. They gave thoughtful insight into lifestyle therapies, medical therapies, and surgical interventions. The presenters were:

W. Timothy Garvey, MD (UAB Diabetes Research Center, University of Alabama at Birmingham)

Lisa M. Neff, MD, MS (Northwestern University Feinberg School of Medicine)

Sangeeta R. Kashyap, MD (Cleveland Clinic Lerner College of Medicine)

  • Blazing Ahead with Advances in the Management of Adult Growth Hormone Disorder (Novo Nordisk Inc. and the Institute for Medical and Nursing Education, Inc.)

Growth hormone deficiency in adults presents with a myriad of possible physical and psychological symptoms. This presentation provided information on the diagnosis and treatment of adult onset growth hormone deficiency (GHC). Furthermore, valuable guidance was provided on transitioning pediatric GHC patients into adults with GHD. The presenters were:

Mark E. Molitch, MD (Northwestern University Feinberg School of Medicine)

David R. Clemmons, MD (University of North Carolina, Chapel Hill)

Julie Silverstein, MD (Pituitary Center, Washington University School of Medicine, St. Louis, MO)

  • Severe Hypoglycemia: The Frequently Forgotten Threat (Lilly USA, LLC.)

Hypoglycemia is one of the top three preventable adverse drug reactions, yet the average yearly incidence of a mild to moderate hypoglycemic episodes in Type 2 Diabetics is 23, with at least one severe event per year. The presenters of this session provide discussion points for providers and patients on anticipating, recognizing, avoiding, and treating hypoglycemic events. They also discuss usefulness of continuous glucose monitors in identifying individual glycemic trends. The presenters were:

Michael T. McDermott, MD (University of Colorado Hospital)

Cecilia C. Low Wang, MD (University of Colorado, Anschutz Medical Campus)

Elizabeth R. Seaquist, MD (University of Minnesota)

Last updated on
First Article From This Meeting:
Moving from High Risk to Low Risk Prevention of CVD Outcomes
close X